These findings are consistent with clinical observations that “1q21 patients” benefit less from high-dose therapy than non-1q21 patients, and that nuclear expression of ILF2 is highly correlated with that of YB1 in 1q21 myeloma. The gene discussed is YBX1; the disease is plasma cell myeloma.